Balsalazide in treating colonic diseases

Bibliography

• Hanauer SB. Medical therapy for ulcerative colitis 2004. Gastroenterology 2004;126:1582-92
   PubMed Web of Science ®Google Scholar
• Scheiber S, Hamling J, Zehnter E, Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate. Gut 1997;40:761-6
   PubMed Web of Science ®Google Scholar
• Levine DS, Riff DS, Pruitt R, A randomized, double blind, dose response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. Am J Gastroenterol 2002;97:1398-407
   PubMed Web of Science ®Google Scholar
• Tursi A. Balsalazide plus high-potency probiotic preparation (VSL[sharp]3) in the treatment of acute mild-to-moderate ulcerative colitis and uncomplicated diverticulitis of the colon. J Clin Gastroenterol 2008;42(Suppl 3 Pt 1):S119-22
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther 2003;17:29-42
   PubMed Web of Science ®Google Scholar
• Eliakim R, Rachmilewitz D. Potential mediators in inflammatory bowel disease. Gastroenterology Int 2002;5:48-56
   Google Scholar
• Grisham MB. Oxidants and free radicals in inflammatory bowel disease. Lancet 1994;344:859-61
   PubMed Web of Science ®Google Scholar
• Hanauer SB. Inflammatory bowel disease. N Engl J Med 1996;334:841-8
   PubMed Web of Science ®Google Scholar
• Gonçalves E, Almeida LM, Dinis TC. Antioxidant activity of 5-aminosalicylic acid against peroxidation of phosphatidylcholine liposomes in the presence of alpha-tocopherol: a synergistic interaction? Free Radic Res 1998;29:53-66
   PubMed Web of Science ®Google Scholar
• Allgayer H. Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther 2003;18:10-4
   PubMed Web of Science ®Google Scholar
• Desreumaux P, Ghosh S. Review article: mode of action and delivery of 5-aminosalicylic acid – new evidence. Aliment Pharmacol Ther 2006;24(Suppl 1):2-9
   PubMedGoogle Scholar
• Dubuquoy L, Rousseaux C, Thuru X, PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut 2006;55:1341-9
   PubMed Web of Science ®Google Scholar
• Ragunath K, Williams JG. Review article: balsalazide therapy in ulcerative colitis. Aliment Pharmacol Ther 2001;15:1549-54
   PubMed Web of Science ®Google Scholar
• Chan RP, Pope DJ, Gilbert AP, Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide. Dig Dis Sci 1983;28:609-15
   PubMed Web of Science ®Google Scholar
• Green JR, Mansfield JC, Gibson JA, A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis. Aliment Pharmacol Ther 2002;16:61-8
   PubMed Web of Science ®Google Scholar
• Mansfield JC, Giaffer MH, Cann PA, A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis. Aliment Pharmacol Ther 2002;16:69-77
   PubMed Web of Science ®Google Scholar
• Nikfar S, Rahimi R, Rezaie A, Abdollahi M. A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis. Dig Dis Sci 2009;54:1157-70
   PubMed Web of Science ®Google Scholar
• Green JR, Lobo AJ, Holdsworth CD, Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group. Gastroenterology 1998;114:15-22
   PubMed Web of Science ®Google Scholar
• Levine DS, Riff DS, Pruitt R, A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. Am J Gastroenterol 2002;97:1398-407
   PubMed Web of Science ®Google Scholar
• Pruitt R, Hanson J, Safdi M, Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. Am J Gastroenterol 2002;97:3078-86
   PubMed Web of Science ®Google Scholar
• Scherl EJ, Pruitt R, Gordon GL, Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study. Am J Gastroenterol 2009;104:1452-9
   PubMed Web of Science ®Google Scholar
• Guarner F, Schaafsma G. Probiotics. Int J Food Microbiol 1998;39:237-8
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Amadini C, Rizzello F, Probiotics – Role in inflammatory bowel disease. Dig Liver Dis 2002;34(Suppl 2):S58-62
   PubMedGoogle Scholar
• Tursi A, Brandimarte G, Papa A, Supplementation with the probiotic VSL#3 in patient.with mild-to-moderate active ulcerative colitis: a double-blind, randomized, placebo-controlled study. Gastroenterology 2009;136:A-64
   Google Scholar
• Miele E, Pascarella F, Giannetti E, Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 2009;104:437-443
   PubMed Web of Science ®Google Scholar
• Elahi B, Nikfar S, Derakhshani S, On the benefit of probiotics in the management of pouchitis in patients underwent ileal pouch anal anastomosis: a meta-analysis of controlled clinical trials. Dig Dis Sci 2008;53:1278-84
   PubMed Web of Science ®Google Scholar
• Chapman TM, Plosker GL, Figgitt DP. VSL#3 probiotic mixture: a review of its use in chronic inflammatory bowel diseases. Drugs 2006;66:1371-87
   PubMed Web of Science ®Google Scholar
• Tursi A, Brandimarte G, Giorgetti GM, Low-dose balsalazide plus high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit 2004;10:PI126-31
   PubMed Web of Science ®Google Scholar
• Tursi A. New physiopathological and therapeutic approaches to the diverticular disease of the colon. Exp Opin Pharmacother 2007;8:299-307
   PubMed Web of Science ®Google Scholar
• Tursi A, Papagrigoriadis S. Review article: the current and evolving treatment of colonic diverticular disease. Aliment Pharmacol Ther 2009:PMID:19549266. [Epub ahead of print]
   Web of Science ®Google Scholar
• Green JR, Gibson JA, Kerr GD, Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group. Aliment Pharmacol Ther 1998;12:1207-16
   PubMed Web of Science ®Google Scholar
• Kruis W, Schreiber S, Theuer D, Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut 2001;49:783-9
   PubMed Web of Science ®Google Scholar
• Green JR, Swan CH, Gibson JA, Patient-led variable dosing with balsalazide as long-term therapy for maintenance in ulcerative colitis: a 3-year prospective observational study. Aliment Pharmacol Ther 2004;19:435-42
   PubMed Web of Science ®Google Scholar
• Floch MH, Fuchs H-M. Modification of stool content by increased bran intake. J Clin Nutr 1978;31(Suppl):185-9
   Google Scholar
• Narayan R, Floch MH. Microscopic colitis as part of the natural history of diverticular disease. Am J Gastroenterol 2002;97(Suppl):112
   Google Scholar
• Tursi A, Brandimarte G, Elisei W, Assessment and grading of mucosal inflammation in colonic diverticular disease. J Clin Gastroenterol 2008;42:699-703
   PubMed Web of Science ®Google Scholar
• Tursi A, Brandimarte G, Elisei W, Faecal calprotectin in colonic diverticular disease: a case-control study. Int J Colorectal Dis 2009;24:49-55
   PubMed Web of Science ®Google Scholar
• Tursi A, Brandimarte G, Giorgetti GM, Balsalazide and/or high-potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon. Int J Colorectal Dis 2007;22:1103-8
   PubMed Web of Science ®Google Scholar
• Borruel N, Casellas F, Antolín M, Effects of nonpathogenic bacteria on cytokine secretion by human intestinal mucosa. Am J Gastroenterol 2003;98:865-70
   PubMed Web of Science ®Google Scholar
• Resbeut M, Marteau P, Cowen D, A randomized double blind placebo controlled multicenter study of mesalazine for the prevention of acute radiation enteritis. Radiother Oncol 1997;44:59-63
   PubMed Web of Science ®Google Scholar
• Jahraus CD, Bettenhausen D, Malik U, Prevention of acute radiation-induced proctosigmoiditis by balsalazide: a randomized, double-blind, placebo controlled trial in prostate cancer patients. Int J Radiat Oncol Biol Phys 2005;63:1483-7
   PubMed Web of Science ®Google Scholar
• Giaffer MH, O'Brien CJ, Holdsworth CD. Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine. Aliment Pharmacol Ther 1992;6:51-9
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Smith M. Critical drug appraisal: olsalazine. Drug Ther Bull 1991;21:57
   Google Scholar
• Foster RA, Zander DS, Mergo PJ, Valentine JF. Mesalamine-related lung disease: clinical, radiographic, and pathologic manifestations. Inflamm Bowel Dis 2003;9:308-15
   PubMed Web of Science ®Google Scholar
• Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut 2002;51:536-9
   PubMed Web of Science ®Google Scholar
• Baker DE. Safety of balsalazide therapy in the treatment of inflammatory bowel disease. Rev Gastroenterol Disord 2005;5:135-41
   PubMedGoogle Scholar
• Kung SJ, Choudhary C, McGeady SJ, Cohn JR. Lack of cross-reactivity between 5-aminosalicylic acid-based drugs: a case report and review of the literature. Ann Allergy Asthma Immunol 2006;97:284-7
   PubMed Web of Science ®Google Scholar
• Muller AF, Stevens PE, McIntyre AS, Experience of 5-aminosalicylate nephrotoxicity in the United Kingdom. Aliment Pharmacol Ther 2005;21:1217-24
   PubMed Web of Science ®Google Scholar
• Robertson E, Austin D, Jamieson N, Hogg KJ. Balsalazide-induced myocarditis. Int J Cardiol 2008;130:e121-2
   PubMed Web of Science ®Google Scholar
• Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis. Reprod Toxicol 2008;25:271-5
   PubMed Web of Science ®Google Scholar
• Ulcerative colitis treatment for children and teens. FDA Consum 2007;41(2):5
   Google Scholar
• Mackowiak JI. A two-stage decision analysis to assess the cost of 5-aminosalicylic acid failure and the economics of balsalazide versus mesalamine in the treatment of ulcerative colitis. Manag Care Interface 2006;19:39-46, 56
   PubMedGoogle Scholar
• Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Comparison of mesalazine and balsalazide in induction and maintenance of remission in patients with ulcerative colitis: a meta-analysis. Dig Dis Sci 2009;54:712-21
   PubMed Web of Science ®Google Scholar
• Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001;96:2929-33
   PubMed Web of Science ®Google Scholar
• Masson S, Nylander D, Mansfield JC. How important is onset of action in ulcerative colitis therapy? Drugs 2005;65:2069-83
   PubMed Web of Science ®Google Scholar
• Schreiber S, Kamm MA, Lichtenstein GR. Mesalamine with MMX technology for the treatment of ulcerative colitis. Expert Rev Gastroenterol Hepatol 2008;2:299-314
   PubMedGoogle Scholar
• Kruis W, Meier E, Schumacher M, Treatment of painful diverticular disease of the colon with mesalamine. A placebo-controlled study. Gastroenterology 2007;132:A-191
   Google Scholar